血清炎症因子与特发性颅内高压患者近期视力下降的相关性研究

doi:10.3969/j.issn.1673-5765.2019.10.006

摘要/Abstract

摘要：

目的探讨特发性颅内高压（idiopathic intracranial hypertension，IIH）患者入院时炎症指标与近期视力下降的相关性。方法对2011年9月-2018年9月在首都医科大学附属北京天坛医院血管神经病学科诊治的58例 IIH患者临床资料进行回顾性分析。根据患者入院时近1个月内是否出现视力下降，分为近期视力下降组（13例）和非近期视力下降组（45例）。应用秩和检验比较两组患者的血清超敏C反应蛋白（hypersensitive C reactive protein，hs-CRP）、红细胞沉降率（erythrocyte sedimentation rate，ESR）、白细胞绝对值、中性粒细胞绝对值、淋巴细胞绝对值、中性粒细胞/淋巴细胞比值等炎症指标的差异。结果近期视力下降组血清hs-CRP及ESR水平显著高于非近期视力下降组[5.50（3.35～8.45）vs 2.60（2.10～2.90）mg/L，P＜0.001；18.0（13.0～24.0）vs 11.0（5.0～14.5）mm/h，P＜0.032]；而血清白细胞绝对值、中性粒细胞绝对值、淋巴细胞绝对值及中性粒细胞/淋巴细胞比值在两组间差异无统计学意义。结论在IIH患者中，存在近期视力下降的患者血清hs-CRP及ESR水平更高，提示炎症反应可能参与 IIH患者视力障碍病程的急性进展。

文章导读： 本研究显示，在特发性颅内高压患者中，存在近1个月内视力下降的患者超敏C反应蛋白水平更高，血沉更快。

关键词: 特发性颅内高压; 炎症因子; 静脉窦狭窄; 视力下降

Abstract:

Objective To investigate the correlation between serum inflammatory factor level and recent visual impairment in patients with idiopathic intracranial hypertension (IIH). Methods Clinical data of 58 patients with IIH who were hospitalized in Department of Neurology, Beijing Tian Tan Hospital from September 2011 to September 2018 were retrospectively analyzed. According to whether patients had visual impairment or not within recent 1 month on admission, they were divided into the recent visual impairment group (n =13) and non-recent visual impairment group (n =45). Kruskal-Wallis test was used to compare the difference of serum hypersensitive C reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), white blood cell counts, neutrophile granulocyte cell counts, lymphocyte cell counts and neutrophile granulocyte / lymphocyte cell ratio and other inflammatory indicators between the two groups. Results Serum hs-CRP and ESR level in the recent visual impairment group were significantly higher than that in non-recent visual impairment group [5.50 (3.35-8.45) vs 2.60 (2.10-2.90) mg/L, P <0.001; 18.0 (13.0-24.0) vs 11.0 (5.0-14.5) mm/h, P <0.032, respectively], while the other inflammatory indicators between the two groups had no statistical difference.

Conclusions The serum hs-CRP and ESR level in IIH patients with recent visual impairment increased significantly, which suggested that inflammatory response may be involved in the pathogenesis of acute progressive visual impairment in IIH patients.

Key words: Idiopathic intracranial hypertension; Inflammatory factor; Venous sinus stenosis;Visual impairment

陈洁, 田雨, 龚浠平, 董可辉, 莫大鹏, 王伊龙（第一作者）. 血清炎症因子与特发性颅内高压患者近期视力下降的相关性研究[J]. 中国卒中杂志, 2019, 14(10): 993-997.

CHEN Jie, TIAN Yu, GONG Xi-Ping, DONG Ke-Hui, MO Da-Peng, WANG Yi-Long. Relationship of Serum Inflammatory Factor and Recent Visual Impairment in Idiopathic Intracranial Hypertension[J]. Chinese Journal of Stroke, 2019, 14(10): 993-997.

参考文献

[1] CORBET J J，SAVINO P J，THOMPSON H S，et

al. Visual loss in pseudotumor cerebri. Follow-up of

57 patients from five to 41 years and a profile of 14

patients with permanent severe visual loss[J]. Arch

Neurol，1982，39（8）：461-474.

[2] WALL M. Sensory visual testing in idiopathic

intracranial hypertension：measures sensitive to

change[J]. Neurology，1990，40（12）：1859-1864.

[3] WALL M，GEORGE D. Idiopathic intracranial

hypertension. a prospective study of 50 patients[J].

Brain，1991，114（Pt 1A）：155-180.

[4] FARB R I，VANEK I，SCOTT J N，et al. Idiopathic

intracranial hypertension：the prevalence and

morphology of sinovenous stenosis[J]. Neurology，

2003，60（9）：1418-1424.

[5] BRUCE B B，PREECHAWAT P，NEWMAN N J，

et al. Racial differences in idiopathic intracranial

hypertension[J]. Neurology，2008，70（11）：861-867.

[6] SIMISTER R，BOWLER J V，WILSON P L，et al.

Transverse venous sinus stenosis and intracranial

hypertension：evidence for which comes first[J]. J

Neurol，2008，255（4）：601-603.

[7] BRUCE B B，KEDAR S，VAN STAVERN G P，et

al. Idiopathic intracranial hypertension in men[J].

Neurology，2009，72（4）：304-309.

[8] BRUCE B B，KEDAR S，VAN STAVERN G P，et

al. Atypical idiopathic intracranial hypertension：

normal BMI and older patients[J]. Neurology，2010，

74（22）：1827-1832.

[9] NORDIC Idiopathic Intracranial Hypertension

Study Group Writing Committee，WALL M，

MCDERMOTT M P，et al. Effect of acetazolamide on visual function in patients with idiopathic

intracranial hypertension and mild visual loss：the

idiopathic intracranial hypertension treatment

trial[J]. JAMA，2014，311（16）：1641-1651.

[10] DINKIN M J，PATSALIDES A. Venous sinus

stenting in idiopathic intracranial hypertension：

results of a prospective trial[J]. J Neuroophthalmol，

2017，37（2）：113-121.

[11] MARKDY K A，MOLLA S P，JENSEN R H，et al.

Understanding idiopathic intracranial hypertension：

mechanisms，management，and future directions[J].

Lancet Neurol，2016，15（1）：78-91.

[12] MCCLUSKEY G，DOHERTY-ALLAN R，

MCCARRON P，et al. Meta-analysis and systematic

review of population-based epidemiological studies

in idiopathic intracranial hypertension[J]. Eur J

Neurol，2018，25（10）：1218-1227.

[13] THAMBISETTY M，LAVIN P J，NEWMAN

N J，et al. Fulminant idiopathic intracranial

hypertension[J]. Neurology，2007，68（3）：229-232.

[14] POLLAK L，ZOHAR E，GLOVINSKY Y，et al.

The laboratory profile in idiopathic intracranial

hypertension[J]. Neurol Sci，2015，36（7）：1189-

1195.

[15] SMITH J L. Whence pseudotumor cerebri?[J]. J Clin

Neuroophthalmol，1985，5（1）：55-56.

[16] 中国高血压防治指南修订委员会. 中国高血压防治

指南2010[J]. 中华心血管病杂志，2011，39（7）：579-

616.

[17] OHMAN E M，BHATT D L，STEG P G，et al. The

REduction of Atherothrombosis for Continued Health

（REACH）Registry：an international，prospective，

observational investigation in subjects at risk for

atherothrombotic events-study design[J/OL]. Am

Heart J，2006，151（4）：786. e1-e10. https：//doi.

org/10.1016/j.ahj.2005.11.004.

[18] WALL M，KUPERSMITH M J，KIEBURTZ K

D，et al. The idiopathic intracranial hypertension

treatment trial：clinical profile at baseline[J]. JAMA

Neurol，2014，71（6）：693-701.